| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| S-8 | Securities offered to employees pursuant to employee benefit plans |
Registration Statements
|
||
| 10-K | Annual report which provides a comprehensive overview of the company for the past year |
Annual Filings
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA |
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
